Please ensure Javascript is enabled for purposes of website accessibility

Why Vir Biotechnology Stock Is Skyrocketing Today

By Prosper Junior Bakiny - Updated Jan 27, 2021 at 1:46PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced some good news regarding one of its COVID-19 programs.

What happened?

Shares of Vir Biotechnology (VIR -0.74%) are soaring through the roof on Wednesday following the company's announcement of the start of a clinical trial to evaluate one of its pipeline candidates as part of a potential combination therapy for COVID-19. As of 1:29 p.m. EST, shares of the biotech are up by 32.5%, after rising by as much as 79% earlier today.

So what

Vir Biotechnology is developing VIR-7831 in collaboration with GlaxoSmithKline (GSK 1.02%). Today, the two drugmakers announced the dosing of the first patient in a clinical trial to assess the efficacy of the combination of VIR-7831 and Eli Lilly's (LLY 1.29%) bamlanivimab in low-risk patients with mild to moderate COVID-19. Eli Lilly originally kicked off a phase 2 clinical trial for bamlanivimab last year.

But the pharma giant is looking to experiment bamlanivimab with other therapies to find effective treatments for all current and future strains of the disease. That is why it decided to expand its ongoing study and team up with Vir Biotechnology and GlaxoSmithKline to test whether the combination of bamlanivimab and VIR-7831 could be an effective treatment.

Face mask with "COVID-19" written on it.

Image source: Getty Images.

Given that Vir Biotechnology is a much smaller company (in terms of market cap) than the other two, it makes sense that the biotech's stock is the only one of the three that is skyrocketing today.

Now what

Vir Biotechnology has already more than doubled this year, and there could be more gains on the horizon for the company if its COVID-19 treatment and other programs pan out. Investors would do well to keep an eye on this biotech.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vir Biotechnology, Inc. Stock Quote
Vir Biotechnology, Inc.
VIR
$24.18 (-0.74%) $0.18
GlaxoSmithKline plc Stock Quote
GlaxoSmithKline plc
GSK
$44.98 (1.02%) $0.46
Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$302.71 (1.29%) $3.86

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.